Wentz A C, Jones G S, Sapp K C, King T M
Am J Obstet Gynecol. 1976 Oct 1;126(3):378-84. doi: 10.1016/0002-9378(76)90554-8.
A progestational action of Danazol has not been reported in the human subject. Danazol administration for 1 month suppressed serum FSH and estradiol values, and the midcycle LH surge; ovulation promptly resumed after treatment. Administration to patients with polycystic ovarian disease resulted in increased LH values, elevated basal temperature, secretory findings in the endometrial biopsy, and menses. Ovarian biopsy did not document corpus luteum formation, and plasma progesterone did not rise. Administration of Danazol to an ovariectomized patients pretreated with estrogen resulted in an atypical endometrial secretory change. Clinical responses to Danazol may in part be explained by a progestational-like effect of the drug.
达那唑在人体中的孕激素作用尚未见报道。给予达那唑1个月可抑制血清促卵泡激素（FSH）和雌二醇值以及月经周期中期促黄体生成素（LH）峰；治疗后排卵迅速恢复。对多囊卵巢疾病患者给药导致LH值升高、基础体温升高、子宫内膜活检出现分泌期表现及月经来潮。卵巢活检未证实有黄体形成，血浆孕酮未升高。对用雌激素预处理的卵巢切除患者给予达那唑可导致非典型的子宫内膜分泌期改变。达那唑的临床反应部分可能由该药物类似孕激素的作用来解释。
